Jump to content
Posted 29 August 2012 - 06:15 PM
This article is focused on the business case for ponatinib but it does include some
interesting data and charts on its efficacy.
0 members, 1 guests, 0 anonymous users
Community Forum Software by IP.Board 3.4.8